<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141136">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01773083</url>
  </required_header>
  <id_info>
    <org_study_id>HepBurn</org_study_id>
    <secondary_id>2012-003289-42</secondary_id>
    <nct_id>NCT01773083</nct_id>
  </id_info>
  <brief_title>Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma</brief_title>
  <acronym>Hepburn</acronym>
  <official_title>Randomized Controlled Trial Investigating the Efficacy and Safety of Nebulized Heparin Versus Placebo in Burn Patients With Inhalation Trauma (Hepburn)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Burns Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <authority>the Netherlands: Central Committee on Research inv. Human Subjects (CCMO)</authority>
    <authority>the Netherlands: Institutional Review Board Amsterdam</authority>
    <authority>Belgium: Federal Agency for medicines and health products (FAGG)</authority>
    <authority>Belgium: Institutional Review Board (Leuven, Ghent, Antwerp; status: to be requested)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this international multi-center double-blind randomized placebo-controlled
      trial is to determine the effect of  nebulized heparin, compared to placebo, on the number
      of ventilator-free days at day 28, in burn patients with confirmed inhalation trauma
      requiring mechanical ventilation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of ventilator-free days at day 28</measure>
    <time_frame>at day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of ventilator-free days is defined as the number of days a patient is breathing without assist of a ventilator during the first 28 days; thus, the patient must be free of mechanical ventilation for 24 hours to have one ventilator-free day; if after successful detubation the patient requires a reintubation due to a surgical procedure, this reintubation will not count as a ventilator day - however, the day(s) will be counted as ventilator day(s) if mechanical ventilation is prolonged after surgery due to respiratory insufficiency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome parameters</measure>
    <time_frame>daily or at day 28 and day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical outcome parameters will include but not be restricted to: (a) length of stay (ICU and hospital); (b) mortality (28- and 90 days); (c) mortality (ICU and hospital); (d) daily Lung Injury Score (LIS); (e) daily Oxygenation Index (OI) ; (f) daily Sequential Organ Failure Assessment (SOFA)-scores ; (g) cumulative dosages of sedatives; (h) incidence of Ventilator-associated Pneumonia (VAP); (i) total number of bronchoscopy-guided cleaning of the larger airway</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory outcome parameters</measure>
    <time_frame>Blood and lavage samples: on admission day and every other day for a maximum period of 14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Levels of markers of coagulation and fibrinolysis in blood and lung lavage fluid, Levels of markers of inflammation in blood and lung lavage fluid, Biomarkers of lung injury in blood and lung lavage fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>daily, for a maximum period of 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety parameters will include but not be restricted to: Occurrence of serious bleedings, any other transfusion of blood products - red cells and/or platelets and/or plasma, Confirmed Heparin induced thrombocytopenia, prolonged activated partial thromboplastin time (aPTT &gt; 150 seconds)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Inhalation Injury</condition>
  <condition>Burn Injury</condition>
  <arm_group>
    <arm_group_label>unfractionated heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25.000 IU/5 ml, will be nebulized 4 hourly (i.e. 6 times daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile sodium chloride (NaCl 0.9%, Pfizer), in 5 ml, will be nebulized every 4 hours (i.e. 6 times daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>unfractionated heparin</intervention_name>
    <description>nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days</description>
    <arm_group_label>unfractionated heparin</arm_group_label>
    <other_name>unfractionated heparin sodium, EV Product Code: SUB02475MIG,</other_name>
    <other_name>Marketing Authorisation number: RVG 01372</other_name>
    <other_name>ATC codes: B01AB01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>sterile sodium chloride (NaCl 0.9%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Age &gt; 18 years

          -  Need for invasive mechanical ventilation

          -  Confirmed inhalation trauma (bronchoscopically)

        Exclusion Criteria:

          -  &gt; 36 hours after trauma

          -  Receiving invasive ventilation &gt; 24 hours

          -  Expected duration of mechanical ventilation &lt; 24 hours

          -  Chronic obstructive pulmonary disease GOLD stage III and IV

          -  Any history of pulmonary hemorrhage in the past 3 months

          -  Any history of significant bleeding disorder

          -  Known allergy to heparin, including heparin-induced thrombocytopenia

          -  Pregnancy or breast feeding

          -  Unlikely to survive for &gt; 72 hours

          -  Total body surface area (TBSA) &gt; 60%

          -  Witnessed or proven aspiration (i.e., confirmed by bronchoscopy)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus J Schultz, Prof. Dr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Koenraad F van der Sluijs, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerie J Glas, MD</last_name>
    <phone>00 31 20 5668222</phone>
    <email>g.j.glas@amc.uva.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Koenraad F van der Sluijs, Dr.</last_name>
    <phone>00 31 20 5669111</phone>
    <email>KvanderSluijs@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barry Dixon, MD</last_name>
      <email>barry.dixon@svhm.org.au</email>
    </contact>
    <investigator>
      <last_name>Barry Dixon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital, Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten</last_name>
    </contact>
    <contact_backup>
      <last_name>Colpaert, MD, Dr.</last_name>
      <email>kirsten.colpaert@ugent.be</email>
    </contact_backup>
    <investigator>
      <last_name>Kirsten Colpaert, MD, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg - Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Muller, MD</last_name>
      <email>jan.muller@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Jan Muller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen- Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manu Malbrain, MD, Dr.</last_name>
      <email>Manu.Malbrain@zna.be</email>
    </contact>
    <investigator>
      <last_name>Manu Malbrain, MD, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marcus J Schultz, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Koenraad F van der Sluijs, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerie J Glas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcel M Levi, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole P Juffermans, Dr. MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Red Cross Hospital, Beverwijk, the Netherlands</name>
      <address>
        <city>Beverwijk</city>
        <state>Noord-Holland</state>
        <zip>1942 LE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Knape, MD</last_name>
      <email>pknape@rkz.nl</email>
    </contact>
    <contact_backup>
      <last_name>David P Mackie, MD</last_name>
      <email>sd.mackie@wxs.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Knape, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David P Mackie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstad Hospital</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barry Cleffken, MD</last_name>
      <email>cleffkenb@maasstadziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Barry Cleffken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martini Hospital</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bert G Loef, MD</last_name>
      <email>b.loef@mzh.nl</email>
    </contact>
    <investigator>
      <last_name>Bert G Loef, MD, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 21, 2014</lastchanged_date>
  <firstreceived_date>January 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Marcus J Schultz</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Inhalation trauma</keyword>
  <keyword>pulmonary coagulopathy</keyword>
  <keyword>heparin nebulization</keyword>
  <keyword>mechanical ventilation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Burns</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
